Ligand (biochemistry)

• Saturated Cannabinoids: Update on Synthesis Strategies and Biological Studies of These Emerging Cannabinoid Analogs (02 Sep 2024)
  
• Probing the Conformational Space of the Cannabinoid Receptor 2 and a Systematic Investigation of DNP (02 Sep 2024)
  
• Pharmacological Evaluation of Cannabinoid Receptor Modulators Using GRABeCB2.0 Sensor (02 Sep 2024)
  
• Motifs in Natural Products as Useful Scaffolds to Obtain Novel Benzo[d]imidazole-Based Cannabinoid Type 2 (CB2) Receptor Agonists (02 Sep 2024)
  
• Mechanistic QSAR analysis to predict the binding affinity of diverse heterocycles as selective cannabinoid 2 receptor inhibitor (02 Sep 2024)
  
• Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism (02 Sep 2024)
  
• Flipping the GPCR Switch: Structure-Based Development of Selective Cannabinoid Receptor 2 Inverse Agonists (02 Sep 2024)
  
• Development of a membrane-based Gi-CASE biosensor assay for profiling compounds at cannabinoid receptors (02 Sep 2024)
  
• Determination of the Cannabinoid CB1 Receptor’s Positive Allosteric Modulator Binding Site through Mutagenesis Studies (02 Sep 2024)
  
• Computational and Experimental Drug Repurposing of FDA-Approved Compounds Targeting the Cannabinoid Receptor CB1 (02 Sep 2024)
  
• A Robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery (02 Sep 2024)
  
• Distinct activation mechanisms regulate subtype selectivity of Cannabinoid receptors (30 Aug 2024)
  
• Structure-Based Virtual Screening and Molecular Dynamics Simulation Assessments of Depsidones as Possible Selective Cannabinoid Receptor Type 2 Agonists (29 Aug 2024)
  
• Structural basis of selective cannabinoid CB2 receptor activation (29 Aug 2024)
  
• Cannabinoid and Opioid Receptor Affinity and Modulation of Cancer-Related Signaling Pathways of Machaeriols and Machaeridiols from Machaerium Pers. (29 Aug 2024)
  
• Understanding the Dynamics of the Structural States of Cannabinoid Receptors and the Role of Different Modulators (28 Aug 2024)
  
• New Insights into Bitopic Orthosteric/Allosteric Ligands of Cannabinoid Receptor Type 2 (28 Aug 2024)
  
• Voltage dependence of the cannabinoid CB1 receptor (27 Aug 2024)
  
• Cannabinoid Conference 2022 (27 Aug 2024)
  
• Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells (25 Aug 2024)
  
• Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules (25 Aug 2024)
  
• The Binding Mode to Orthosteric Sites and/or Exosites Underlies the Therapeutic Potential of Drugs Targeting Cannabinoid CB2 Receptors (21 Aug 2024)
  
• Non-Canonical Cannabinoid Receptors with Distinct Binding and Signaling Properties in Prostate and Other Cancer Cell Types Mediate Cell Death (21 Aug 2024)
  
• Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects (21 Aug 2024)
  
• Artificial Intelligent Deep Learning Molecular Generative Modeling of Scaffold-Focused and Cannabinoid CB2 Target-Specific Small-Molecule Sublibraries (21 Aug 2024)
  
• Virtual Screening of C. Sativa Constituents for the Identification of Selective Ligands for Cannabinoid Receptor 2 (20 Aug 2024)
  
• Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products (20 Aug 2024)
  
• Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases (20 Aug 2024)
  
• Cholesterol as a modulator of cannabinoid receptor CB2 signaling (20 Aug 2024)
  
• Antidepressant-Like Effect of Terpineol in an Inflammatory Model of Depression: Involvement of the Cannabinoid System and D2 Dopamine Receptor (20 Aug 2024)
  
• Structure-Based Identification of Potent Natural Product Chemotypes as Cannabinoid Receptor 1 Inverse Agonists (19 Aug 2024)
  
• Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines (19 Aug 2024)
  
• Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An In Silico study (19 Aug 2024)
  
• Synthesis, Biodistribution and In vitro Evaluation of Brain Permeable High Affinity Type 2 Cannabinoid Receptor Agonists [11C]MA2 and [18F]MA3 (18 Aug 2024)
  
• Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis (18 Aug 2024)
  
• Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes (18 Aug 2024)
  
• New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists (05 Sep 2022)
  
• Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses (01 Sep 2022)
  
• Identification of Novel Antagonists Targeting Cannabinoid Receptor 2 Using a Multi-Step Virtual Screening Strategy (01 Sep 2022)
  
• 1,2,3-Triazole derivatives as highly selective cannabinoid receptor type 2 (CB2) agonists (27 Aug 2022)
  
• Cannabinoids and COVID-19 (25 Jul 2022)